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Abstract
Background: To identify success predictors and to study the role of the fellow untreated eye as a co-variable for
adjustment of intraocular pressure (IOP) outcomes following selective laser trabeculoplasty (SLT) in early open-angle
glaucoma (OAG) patients.
Methods: A case series was carried out. Patients with uncontrolled early OAG or ocular hypertension (inadequate
IOP control requiring additional treatment) underwent SLT (one single laser session) performed by the same
surgeon in a standardized fashion. The same preoperative medical regimen was maintained during follow-up
for all patients. Post-treatment assessments were scheduled at week 1 and months 1, 2, and 3. In order to
account for possible influence of IOP fluctuation on laser outcomes, post-laser IOP values of the treated eye of each
patient were also analyzed adjusting for IOP changes (between visits variation) of the untreated fellow eye (adjusted
analysis). Pre and post-laser IOP values were compared using paired t-test. Factors associated with the magnitude of
IOP reduction were investigated using multiple regression analysis.
Results: A total of 45 eyes of 45 patients were enrolled. Mean IOP was reduced from 20.8 ± 5.1 to 14.9 ± 2.
9 mmHg at month 3 (p < 0.001). Adjusted success rate (defined as IOP reduction ≥ 20%) was 64% and mean
percentage of IOP reduction was 23.1 ± 14.3% at last follow-up visit. Considering unadjusted post-laser IOP
values, it was found a 20% greater absolute IOP reduction (median [interquartile range] 6 mmHg [4–7] vs
5 mmHg [3–7]; p = 0.04), with a success rate of 76%. Although baseline IOP was significantly associated with
both adjusted and unadjusted post-laser IOP reduction, a stronger association was found when unadjusted
IOP values were considered (p < 0.001 and R2 = 0.35; p < 0.001 and R2 = 0.67, respectively). Age, mean deviation
(MD) index, central corneal thickness and type of glaucoma were not significant predictors (p ≥ 0.150).
Conclusions: In this group of patients with early OAG or ocular hypertension, our short-term results confirmed SLT
as a safe and effective alternative for IOP reduction. Although better outcomes were found in eyes with
higher preoperative IOP, this effect was mitigated when results were adjusted to the fellow untreated eye
(to the influence of between visits-IOP fluctuations).
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Background
Glaucoma is one of the most common optic neuropa-
thies, characterized by progressive retinal ganglion cells
loss, changes in the appearance of the optic disc and
visual field damage [1]. Until nowadays, elevated intraoc-
ular pressure (IOP) remains the major known risk factor
for glaucoma development and progression [2, 3].
Several large randomized clinical trials underscored that
the only proven method to treat glaucoma is the
reduction of the IOP toward a target level that will avoid
functional impairment by slowing the rate of disease
progression [2, 4–6]. Usually, the initial target aims for a
20 to 50% reduction on pressure, depending on baseline
IOP values, disease stage and patient’s life expectancy
[7]. Depending on the progression of the disease, the tar-
get pressure may need to be readjusted during follow-up
[7]. Intraocular pressure may be lowered by using topical
medications, incisional surgery, or laser procedures [7].
When it comes to laser surgery, the two main options
available are argon laser trabeculoplasty (ALT) and
selective laser trabeculoplasty (SLT) [8].
Latina and coworkers have introduced SLT in 1995,
providing us with a safe and effective non-invasive
treatment modality for patients with open-angle
glaucoma (OAG) and ocular hypertension (OH) [9, 10].
SLT lowers IOP by inducing biological changes in the
trabecular meshwork resulting in increased aqueous
outflow [9, 10]. It is performed with a Q-switched Nd:
yttrium-aluminum-garnet (YAG) laser (λ = 532 nm),
that delivers short burst of low-fluence laser energy to
selected melanin-containing cells in the trabecular
meshwork, causing intracellular targeting of the pigmen-
ted trabecular meshwork cells without damage to adja-
cent no pigmented cells or structures [9].
Several studies with follow-up ranging from 4 weeks
to 72 months demonstrated the efficacy of SLT as an
IOP lowering modality, with an average success rate of
70% [10–13]. Some recent data have suggested SLT as
initial therapy, especially for eyes with early disease or
high-risk OH [14]. Although substantial IOP reductions
can be achieved in the majority of patients, the final
SLT effect may vary significantly between patients. As
approximately 30% of the patients do not respond to
SLT therapy, it would be important to identify predictors
of success [10–13].
In few previous reports that investigated factors
associated with the magnitude of IOP reduction follow-
ing SLT, the only significant predictor that has been
consistently documented is baseline IOP (it is not clear
until now whether this association could in part just be
an effect of regression to the mean [15–17]) [10–13]. As
these studies did not focus specifically on eyes with early
glaucoma and most importantly did not adjust post-laser
IOP results to the influence of between visits-IOP
fluctuations, [10–13] we sought to determine success
predictors and to study the role of the fellow untreated
eye as a covariable for adjustment of IOP outcomes
following SLT in early OAG or ocular hypertension
patients.
Methods
This case series study adhered to the tenets of the
Declaration of Helsinki and was approved by the Institu-
tional Review Board of the Federal University of São
Paulo. Additionally, written informed consent was ob-
tained from all participants.
Study participants
We prospectively enrolled patients with uncontrolled
early OAG or OH (inadequate IOP control requiring
additional treatment). All participants underwent a
complete ophthalmological examination including re-
view of medical history, best-corrected visual acuity, IOP
measurement with Goldmann applanation tonometry
(Haag-Streit, Koeniz, Switzerland), slit-lamp biomicro-
scopy, gonioscopy, refraction and dilated fundus examin-
ation. Key Exclusion criteria were previous glaucoma
surgery, history of ocular trauma or inflammation, and
visual field mean deviation (MD) index worse than -6
decibels (dB).
All patients had early OAG or OH with uncontrolled
IOP (individualized for each patient, based on the level
of glaucomatous damage and/or based on disease pro-
gression [visual field progression confirmed by at least
three visual field test or structural damage confirmed by
stereophotograph]); age >18 years and no previous laser
or incisional glaucoma surgery.
The definition of OAG was based on the presence of
repeatable (≥3 consecutive) abnormal standard auto-
matic perimetry (SAP) test results on the 24-2 program
of the visual field (Humphrey Field Analyzer; Carl Zeiss
Meditec, Inc) or if progressive glaucomatous optic disc
changes were noted on masked examination of stereo
photographs, regardless of the results of SAP. We
defined abnormal SAP results as those with a pattern
standard deviation index outside the 95% confidence
limits or glaucoma hemifield test results outside the
reference range. Early glaucoma was defined as charac-
teristic OAG and reproducible visual field loss, with
visual field mean deviation index better than -6 dB [18].
OH was defined as of IOP higher than 21 mmHg, with
healthy-appearing optic discs and without repeatable
abnormal SAP results. OH had at least three IOP mea-
surements in each eye at pre-laser time points.
Selective Laser Trabeculoplasty (SLT)
All participants underwent SLT (one single laser session)
performed by the same surgeon in a standardized
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fashion. The same preoperative medical regimen was
maintained during follow-up for all patients. Post-
treatment assessments were scheduled at week 1 and
months 1, 2, and 3. The IOP was measured with a
Goldmann Tonometer.
All patients underwent to one session of SLT using a
frequency-doubled Q-switched Nd:YAG laser (Laserex
Tango™ Nd:YAG, Ellex Medical, Australia) emitting at
532 nm with pulse duration of 3 nanoseconds and a
spot size of 400 μm coupled to a slit- lamp delivery
system. A Goldmann 3-mirror goniolens was placed
on the eye with 1% methylcellulose. The aiming beam
was focused onto the pigmented trabecular meshwork.
The 400 μm spot size was large enough to irradiate
the entire anteroposterior height of the trabecular
meshwork. In all eyes, approximately 100 adjacent but
nonoverlapping laser spots were placed over 360° of
the trabecular meshwork. Initial energy level was set
to 0.80 mJ and changed according to the level of tra-
becular meshwork pigmentation. The end point of
each laser application was minibubble formation.
Brimonidine 0.2% was instilled before and after the
procedure, and 0.1% dexamethasone acetate was
administrated 4 times a day for 5 days in all patients.
Data collected included age, gender, race, type of
OAG, visual field status, preoperative (average of 3
separate measurements) and postoperative IOP, number
of antiglaucomatous medications, gonioscopy appear-
ance, pachymetry, surgical complications, and any subse-
quent related event.
Statistical analysis
Descriptive statistics included mean and standard
deviation values for normally distributed variables,
while those not normally distributed were presented
with median and interquartile range. Skewness/
Kurtosis tests and histograms were used to check
Normality. Paired t-test was used for comparison of
IOP values between each time point (baseline and
post-laser treatment). For non-normally distributed
variables we used a non-parametric test (Wilcoxon
rank-sum test).
In order to account for possible influence of IOP
fluctuation on laser outcomes, post-laser IOP values
of the treated eye of each patient were also analyzed
adjusting for IOP changes (between visits variation)
of the untreated fellow eye (adjusted analysis).
Factors associated with the magnitude of IOP reduc-
tion were investigated using multiple regression
analysis.
All statistical analyses were performed with commer-
cially available software (MedCalc software; MedCalc,
Inc., Mariakerke, Belgium). The α level (type I error) was
set at 0.05.
Results
A total of 45 eyes of 45 patients were enrolled.
Among these patients, 32 (72%) had primary OAG, 4
(9%) had pigmentary glaucoma, 6 (13%) had OH, and
3 (6%) had exfoliative glaucoma. Mean age and
average SAP MD for this sample were 57.6 ± 11.7 years
and -2.3 ± 1.8 dB, respectively. Demographic and
clinical data of these patients are presented in details
in Table 1. According to the Spaeth grading of pig-
ment on the trabecular meshwork, [19] 70% patients
had moderate pigmentation (PTM ++, from PTM + to
PTM +++) and all patients had open angle (visible
until at least the scleral spur in all quadrants during
the gonioscopy). Table 2 shows details about mean
IOP in each post-treatment assessment.
Adjusted success rate (defined as IOP reduction ≥
20%) was 64% and mean percentage of IOP reduction
was 23.1 ± 14.3% at last follow-up visit. Figure 1 shows
for adjusted success rate, the mean IOP at baseline and
last follow-up visit. Considering unadjusted post-laser
IOP values, it was found a 20% greater absolute IOP re-
duction (median [interquartile range] 6 mmHg [4–7] vs
5 mmHg [3–7]; p = 0.04), with a success rate of 76%.
Figure 2 shows for unadjusted success rate, the mean
IOP at baseline and last follow-up. And Table 3 summa-
rizes the laser outcomes for adjusted and non-adjusted
success rate.
In the univariable regression analysis, although base-
line IOP was significantly associated with both adjusted
and unadjusted post-laser IOP reduction, a stronger
association was found when unadjusted IOP values were
Table 1 Demographic and clinical variables of study patients
(n = 45)
Characteristic Value
Age (±SD), years 57.6 ± 11.7
Gender, % M (47%), F (53%)
Race, % W (75%), A (6%), B (12%), M (7%)
Type of Glaucoma, % POAG (72%), OH (13%), PG (9%),
EG (6%)
Baseline mean IOP (±SD), mmHg 20.8 ± 5.1 (range 12 to 39)
Non-adjusted post-laser mean
IOP (±SD), mmHg
14.98 ± 2.89 (range 10 to 22)
Adjusted post-laser mean
IOP (±SD), mmHg
15.71 ± 4.06 (range 7 to 31)
Number of Medications (±SD) 1.4 ± 1.2 (range 0 to 4)
Average SAP MD (±SD), dB -2.3 ± 1.8 (range -5.9 to 0.4)
Pachymetry (±SD), μm 520.8 ± 42.6 (range 444 to 624)
Abbreviations: SD standard deviation, M male, F female, W white, A Asian,
B Black, M Mixed, IOP Intraocular pressure, mmHg millimeter of mercury,
POAG primary open angle glaucoma, OH ocular hypertension, PG pigmentary
glaucoma, EG exfoliative glaucoma, SAP standard automatic perimetry,
MD mean deviation
Chun et al. BMC Ophthalmology  (2016) 16:206 Page 3 of 8
considered (p < 0.001 and R2 = 0.35; p < 0.001 and R2 =
0.67; respectively).
In the multiple regression analysis, the only factor
significantly associated with the magnitude of IOP re-
duction (adjusted values) was baseline IOP (p < 0.001
and R2 = 0.46). Figure 3 illustrates the relationship
between the magnitude of IOP reduction (adjusted
values) and baseline IOP. Age, MD index, central
corneal thickness, type of glaucoma and number of
medications at the baseline were not significant for
this model (p ≥ 0.150).
During the follow-up visits, one patient developed
sustained IOP rise (≥10% IOP increase in 2 consecutive
visits). There were no cases of peripheral anterior
synechiae development or any other serious complica-
tion. Finally, three patients had sustained high IOP
(≥21 mmHg after 3 months follow-up). Mean age and
average SAP MD for these three patients were 50.5 ±
6.4 years and -2.1 ± 0.4 dB, respectively. Consequently,
they were treated with eye drop medications. Incisional
surgery was not required for any patient. These three
patients are currently being followed with no visual field
progression.
Discussion
This study has shown that in early glaucomatous
disease, SLT is safe and effective for IOP reduction.
In addition, using the unadjusted analysis of post-
laser IOP we tend to overestimate success rates (the
influence of IOP fluctuations between the visits). To
the best of our knowledge, this is the first study that
provides evidence that the fellow untreated eye
should be considered to allow post-laser outcomes
adjustment.
Different studies have tried to determine the predic-
tors of success for adjuvant SLT in OAG in different
populations [20–25]. The different factors that have
been consistently described to predict SLT success
throughout the literature include: no prior antiglauco-
matous medication use [22, 24, 25] and a higher
baseline IOP [20, 21, 23]. This relationship between
SLT success and baseline IOP has been underscored
in previous publications [20, 21, 23]. Kano et al. stud-
ied 67 eyes of 67 uncontrolled OAG patients that
underwent SLT and they showed that the measure of
preoperative IOP was the significant determinant for
success [21]. Alternatively, Damji et al. conducted a
clinical trial with 36 eyes comparing SLT vs argon
laser trabeculoplasty (ALT) and they found out that
the only predictor of final IOP at 6 months was the
baseline IOP [20]. In addition, in a retrospective
study, Rhodes et al. observed that patients with
higher preoperative IOPs had a greater reduction in
IOP in both eyes [26]. In a prospective interventional
study, Koucheki and Hashemi also found significant
correlation between the preoperative IOP level and
Table 2 Intraocular pressure values (mmHg) at each time point
Baseline 1 week Post-treatment 1 month Post-treatment 3 months Post-treatment
Mean IOP (± SD) mmHg 20.8 ± 5.0 18.8 ± 5.1 16.8 ± 5.4 15.0 ± 2.9
Fig. 1 Box plots showing for adjusted success rate, the mean intraocular pressure at baseline and last follow-up visit. * Box represents median
and interquartile range. Whiskers correspond to maximum and minimum 1.5 interquartile range (IQR)
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the IOP reduction after SLT [27]. In our study, base-
line IOP was the only factor significantly associated
with SLT success. Even though we have focused on
eyes with early glaucoma (SAP MD better than
-6 dB) or OH, our results are in agreement with
those previously reported studies with glaucomatous
patients with different disease stages, as they also
found a positive association between baseline IOP
and magnitude of IOP reduction [20, 26–28].
When we analyzed different aspects such as age,
SAP MD index, central corneal thickness and type of
glaucoma, no significant association was found in this
present study. These findings are also in agreement
with previous SLT publications that showed no cor-
relation for sex, age, previous ocular surgery, lens sta-
tus, classes of antiglaucomatous medications, angle
pigmentation or type of OAG [26–29]. It is true that
some studies found correlation between age and SLT
success rates. For example, Ahmed et al. found that
age older than 60 years was associated with greater
SLT success rates and Lee et al. also described that
older age was found to be a significant predictor for
success (Odds Ratio: 1.11; p = 0.0003) [30, 31]. The
reason for this disagreement may be due to different
characteristics of these samples. Our patients had a
mean age of 57.6 years old that is higher than the
other two studies.
Regarding the association between SLT outcomes
and type of glaucoma, we have not found significant
association in this present study. It is true that Chen
et al. showed that pigmentation at the trabecular
meshwork is related to the pressure-lowering effect of
SLT 7 months after the SLT treatment [32]. However,
according to Hodge et al., the pigmentation of tra-
becular meshwork and type of glaucoma did not pre-
dict better outcome [33]. The methods used by Chen
et al. included 32 patients in two different groups
who received SLT with 25 laser spots on 90° of tra-
becular meshwork, the other 32 patients who received
SLT with 50 laser spots on 180° of trabecular mesh-
work and were followed for 7 months post-treatment
[32]. Alternatively, Hodge et al. included 89 random-
ized patients who were followed by 12 months post-
treatment [33]. Therefore, it is possible that the
different methodology applicable in different studies
can lead to these different results. Future studies
should be necessary to evaluate the real impact of
type of glaucoma and trabecular meshwork pigmenta-
tion in SLT outcomes.
In our sample, we described one case (2%) of sustained
IOP rise (≥10% IOP increase in 2 consecutive visits) that
resolved without additional treatment. There were no
cases of peripheral anterior synechiae development or
any other serious complication. This incidence is also in
Fig. 2 Box plots showing for unadjusted success rate, the mean intraocular pressure at baseline and last follow-up visit. * Box represents median
and interquartile range. Whiskers correspond to maximum and minimum 1.5 interquartile range (IQR)
Table 3 Laser Outcomes for adjusted and non-adjusted
success rates
Variables Adjusted Non-adjusted
Delta IOP (±SD), mmHg 5.1 ± 3.8 (range -2
to 21)
5.8 ± 3.8 (range 0
to 20)
Delta IOP (±SD), % 23.1 ± 14.3 (range -14.3
to 75)
26 ± 12.6 (range 0
to 51.3)
Success Rate, % 64% 76%
Abbreviations: IOP intraocular pressure, SD standard deviation, mmHg
millimeter of mercury
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agreement with reported literature. Most reported ad-
verse effects for SLT such as discomfort, pain or photo-
phobia are mild and resolve within few days without
treatment [34, 35]. The transient IOP rise of ≥5 mmHg
occurs in 0 to 28% of eyes studied, [13, 36, 37] and
≥10 mmHg in up to 5.5% of eyes [13, 23]. It usually
resolves quickly with or without topical antiglaucoma-
tous treatment, usually within 24 h. Other side effects
reported in the literature are: peripheral anterior syne-
chiae, hyphema, bilateral anterior uveitis and choroidal
effusion [36, 38, 39]. There were no cases of these com-
plications in this present study during 3-months follow-
up. We also reported three patients (7%) with sustained
high IOP (≥21 mmHg after 3 months follow-up). This
result is not surprising, as previous studies have shown
that SLT is not effective in 20–30% of the cases [13].
Moreover, the key finding of the present study was
the difference between adjusted and non-adjusted
post-laser results. As without accounting for the
influence of IOP variation we found an overestimated
lowering effect, therefore the main clinical implica-
tions of our findings is that it seems reasonable to
treat one eye at a time and use the IOP values of the
untreated fellow eye as controls. Probably, the associ-
ation between baseline IOP and post-laser IOP results
found in different previous studies is partially related
to the effect of regression to the mean [15–17]. It is
true that previous studies have reported a modest
contralateral effect in the untreated fellow eyes of
patients undergoing selective laser trabeculoplasty.
Given that mechanism of effect of SLT on IOP reduc-
tion is considered to be a biological process it is
possible that there is contralateral reduction in
response to the SLT laser. However, this fact cannot
exclude the regression to mean.
It is important to discuss some specific limitations
of the present study. First, it is limited by its small
sample size; however even with a small sample we
found a significant difference between unadjusted
analysis of post-SLT IOP and the non-adjusted one,
and in addition this is the first study focused on
early glaucoma patients. However, future studies
should be necessary to confirm this hypothesis.
Second, the 3-month IOP was used for the calcula-
tion of IOP response. A longer period following SLT
would have been more ideal to estimate the real
success rate. Third, topical antiglaucomatous medica-
tions were not washed out prior to SLT procedure.
However, we considered unethical and inappropriate
to stop antiglaucomatous medication in these pa-
tients. Additionally, as reported in the literature, the
use of eye drops medication did not seem to influ-
ence SLT success significantly [28]. Lastly, we have
not analyzed different aspects that could influence
the SLT final results such as greater degree of spher-
ical equivalent or more refractive error. Lee et al.
recruited 51 eyes of 31 patients from Chinese popu-
lation and they found that greater degree of spherical
equivalent or more refractive error was a predictor of
SLT success (Odds Ratio: 1.19; p = 0.02) [31].
Although this is an interesting point, this is not the
main purpose of this study; therefore, future studies
can be carried out from Brazilian population to
elucidate this question.
Fig. 3 Scatter plot depicting the relationship between the magnitude of intraocular pressure reduction (adjusted values) and baseline
intraocular pressure
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Conclusions
In conclusion, our results suggest that SLT is safe and
effective for IOP reduction in OHT and early OAG.
Higher IOP reduction was found in those with higher pre-
laser IOP. We found that success was overestimated if the
post-laser IOP was not adjusted for the inter visit variation
in the other eye. We, therefore suggest that, whenever
possible, laser should be performed in one eye at a time
thus allowing for post-laser outcomes adjustment. How-
ever, analysis of visual field progression and structural
examination should be always taking into account for a
better understanding of the treatment impact.
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